SENTI-202

N/A

Report date: 2025/12/12 15:30:37

Base Information

Drug NameSENTI-202

Drug Alias NameSENTI-202

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionNatural killer cell replacementsTyrosine-protein kinase receptor FLT3 inhibitorsAnti-Myeloid cell surface antigen CD33 +[4]

TargetsTyrosine-protein kinase receptor FLT3Myeloid cell surface antigen CD33

Therapy Area/IndicationsMyelodysplastic SyndromesHematologic NeoplasmsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustralia

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesSenti Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesSenti Biosciences Inc

Inactive CompaniesN/A

Active IndicationsMyelodysplastic SyndromesHematologic NeoplasmsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A